Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05164133 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT05164133 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 2 participants.
The verdict
NCT05164133, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a single-arm, open-label study to assess the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of tocilizumab (TCZ) for the treatment of pediatric patients from birth to less than 18 years old hospitalized with COVID-19 and who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.
Interventions
- DRUG Tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-06-10 |
| Est. Completion | 2024-03-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05164133
The ClinicalTrials.gov registry entry for NCT05164133 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tocilizumab is the first listed.
NCT05164133 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05164133 about?
NCT05164133 is a clinical study titled "A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19". This is a single-arm, open-label study to assess the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of tocilizumab (TCZ) for the treatment of pediatric patients from birth to less than 18 years old hospitalized with COVID-19 and who are receiving systemic corticosteroids and re...
What is the current status of trial NCT05164133?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2022-06-10. Estimated completion is 2024-03-27.
What interventions are being tested in trial NCT05164133?
The interventions under investigation include: Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT05164133?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.